Cowen and Company lowered shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from an outperform rating to a market perform rating in a research note released on Friday morning. They currently have $9.00 target price on the stock.

Analyst Recommendations for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Several other equities research analysts also recently commented on the company. Wedbush reissued a neutral rating and issued a $4.00 price objective (down previously from $9.00) on shares of Raptor Pharmaceutical Corp. in a report on Monday, September 12th. FBR & Co reissued a hold rating on shares of Raptor Pharmaceutical Corp. in a report on Thursday, September 8th. Zacks Investment Research raised Raptor Pharmaceutical Corp. from a hold rating to a buy rating and set a $7.50 price objective for the company in a report on Thursday, August 11th. Finally, Citigroup Inc. downgraded Raptor Pharmaceutical Corp. from a buy rating to a neutral rating and increased their price objective for the company from $6.00 to $8.00 in a report on Monday, August 8th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $7.93.

Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 8.99 on Friday. Raptor Pharmaceutical Corp. has a one year low of $2.94 and a one year high of $8.99. The company’s market cap is $766.90 million. The firm has a 50-day moving average of $7.50 and a 200 day moving average of $5.73.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company earned $32.05 million during the quarter, compared to analysts’ expectations of $28.52 million. Raptor Pharmaceutical Corp. had a negative net margin of 79.29% and a negative return on equity of 66.67%. The business’s quarterly revenue was up 37.4% on a year-over-year basis. During the same period last year, the business earned ($0.17) EPS. Equities research analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

Several large investors have recently bought and sold shares of the company. BlackRock Fund Advisors boosted its position in shares of Raptor Pharmaceutical Corp. by 4.4% in the second quarter. BlackRock Fund Advisors now owns 3,330,692 shares of the company’s stock worth $17,886,000 after buying an additional 141,019 shares during the last quarter. Sarissa Capital Management LP boosted its position in shares of Raptor Pharmaceutical Corp. by 5.5% in the second quarter. Sarissa Capital Management LP now owns 2,875,000 shares of the company’s stock worth $15,438,000 after buying an additional 150,000 shares during the last quarter. State Street Corp boosted its position in shares of Raptor Pharmaceutical Corp. by 42.4% in the second quarter. State Street Corp now owns 1,947,089 shares of the company’s stock worth $10,454,000 after buying an additional 580,140 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Raptor Pharmaceutical Corp. by 1.6% in the second quarter. UBS Asset Management Americas Inc. now owns 1,288,685 shares of the company’s stock worth $6,920,000 after buying an additional 20,650 shares during the last quarter. Finally, Ghost Tree Capital LLC bought a new position in shares of Raptor Pharmaceutical Corp. during the second quarter worth approximately $3,222,000. 54.91% of the stock is owned by institutional investors.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

5 Day Chart for NASDAQ:RPTP

Receive News & Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.